文献速递前列腺癌

全血AR-FL与AR-V1预测去势抵抗性前列腺癌对阿比特龙应答

Analysis of AR-FL and AR-V1 in Whole Blood of Patients with Castration Resistant Prostate Cancer as a Tool for Predicting Response to Abiraterone Acetate.
PubMed 文献 · J Urol · 2020-02-18

该研究在102例去势抵抗性前列腺癌患者中,通过逆转录定量PCR检测全血循环雄激素受体全长(AR-FL)及剪接变异体(AR-V1、AR-V3、AR-V7),评估其作为阿比特龙醋酸酯治疗耐药生物标志物的价值。结果显示AR-FL和/或AR-V1高水平患者无进展生存期和总生存期最短(p<0.0001),提示全血AR-FL或AR-V1可作为预测原发耐药和监测获得性耐药的血液标志物。

要点

  • 全血AR-FL或AR-V1高水平与阿比特龙治疗最短PFS和OS相关(p<0.0001)。
  • AR-V1在应答时间短和中等患者中表达量最高。
  • 全血AR-FL/AR-V1可作为预测阿比特龙原发耐药的血液标志物。

核心结论

  • 全血循环AR-FL或AR-V1可作为识别阿比特龙醋酸酯原发耐药的血液生物标志物,并用于监测治疗中de novo耐药的发生。

研究设计与样本

  • 前瞻性收集102例去势抵抗性前列腺癌患者阿比特龙治疗前及治疗中的185份连续血样,通过逆转录定量PCR检测AR-FL、AR-V1、AR-V3和AR-V7。
  • 另对112份前列腺标本进行回顾性分析以评估上述指标。

主要发现

  • AR-FL在所有血样中均可检出;AR-V1、AR-V3、AR-V7及至少一种剪接变异体检出率分别为17%、55%、65%和81%。
  • AR-V1表达量在应答时间短和中等患者中最高,高于应答时间延长者。
  • AR-FL和/或AR-V1水平较高的患者无进展生存期和总生存期最短(p<0.0001)。

临床怎么用

  • 可考虑检测全血AR-FL和AR-V1水平,辅助筛选可能对阿比特龙原发耐药的去势抵抗性前列腺癌患者。
  • 治疗期间动态监测全血AR-FL/AR-V1或有助于早期发现获得性耐药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Reliable molecular diagnostic tools are still unavailable for making informed treatment decisions and monitoring the response in patients with castration resistant prostate cancer. We evaluated the significance of whole blood circulating androgen receptor transcripts of full length (AR-FL) and splice variants (AR-V1, AR-V3 and AR-V7) as biomarkers of abiraterone acetate treatment resistance in patients with castration resistant prostate cancer. MATERIALS AND METHODS: After retrospective analysis in 112 prostate specimens AR-FL, AR-V1, AR-V3 and AR-V7 were evaluated in 185 serial blood samples, prospectively collected from 102 patients with castration resistant prostate cancer before and during abiraterone acetate therapy via reverse transcription quantitative polymerase chain reaction. RESULTS: AR-FL was present in all samples while AR-V1, AR-V3, AR-V7 and at least 1 of them was detected in 17%, 55%, 65% and 81% of castration resistant prostate cancer blood samples, respectively. The highest amount of AR-V1 was found in blood of patients whose response time was short and medium in comparison to extended. Patients with a higher level of AR-FL and/or AR-V1 had the shortest progression-free survival and overall survival (p <0.0001). CONCLUSIONS: Blood circulating AR-FL or AR-V1 can serve as blood based biomarkers for identification of the primary resistance to abiraterone acetate and the tool to monitor de novo resistance development during abiraterone acetate treatment.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Stuopelyte K, Sabaliauskaite R, Bakavicius A, et al. Analysis of AR-FL and AR-V1 in Whole Blood of Patients with Castration Resistant Prostate Cancer as a Tool for Predicting Response to Abiraterone Acetate. J Urol. 2020. PMID: 32068491. doi:10.1097/JU.0000000000000803

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。